INFI - インフィニティ・ファ―マシュ―ティカルズ （Infinity Pharmaceuticals Inc.）

Infinity Pharmaceuticals'' primary drug showed encouraging results, but company is waiting on a collaboration deal. Read here for an investment analysis on INFI.

In last trading session, Infinity Pharmaceuticals Inc. (NASDAQ:INFI) saw 0.34 million shares changing hands with its beta currently measuring 2.04. Company’s recent per share price level of $1.52 trading at $0.02 or 1.33% at ring of the bell on the day assigns it a market valuation of $148.60M. That closing price of INFI’s stock is … Infinity Pharmaceuticals Inc. (NASDAQ:INFI) Share Price Rebounds 69.74% From The Lows – But Can It Keep Going? Read More »

The trading price of Infinity Pharmaceuticals Inc. (NASDAQ:INFI) floating higher at last check on Wednesday, August 24, closing at $1.59, 2.58% higher than its previous close. Traders who pay close attention to intraday price movement should know that it has been fluctuating between $1.29 and $1.57. In examining the 52-week price action we see that … What Do Analysts Think About Infinity Pharmaceuticals Inc.’s (NASDAQ:INFI) Future? Read More »

As of Monday, Infinity Pharmaceuticals Inc.’s (NASDAQ:INFI) stock closed at $1.34, down from $1.46 the previous day. While Infinity Pharmaceuticals Inc. has underperformed by -8.22%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, INFI fell by -55.63%, with highs and lows ranging from $3.89 to $0.46, […]

https://www.investing.com/news/pro/jones-trading-downgrades-infinity-pharmaceutical-to-hold-432SI-2871671

The trading price of Infinity Pharmaceuticals Inc. (NASDAQ:INFI) floating higher at last check on Wednesday, August 24, closing at $1.59, 2.58% higher than its previous close. Traders who pay close attention to intraday price movement should know that it has been fluctuating between $1.29 and $1.57. In examining the 52-week price action we see that … What Do Analysts Think About Infinity Pharmaceuticals Inc.’s (NASDAQ:INFI) Future? Read More »

As of Monday, Infinity Pharmaceuticals Inc.’s (NASDAQ:INFI) stock closed at $1.34, down from $1.46 the previous day. While Infinity Pharmaceuticals Inc. has underperformed by -8.22%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, INFI fell by -55.63%, with highs and lows ranging from $3.89 to $0.46, […]

https://www.investing.com/news/pro/jones-trading-downgrades-infinity-pharmaceutical-to-hold-432SI-2871671

At the close of the New York Stock Exchange, the Dow Jones rose 1.63% to a 3-month high, the S&P 500 rose 2.13% and the NASDAQ Composite rose 2.89%. The leading performer among the components of the Dow Jones index today was Walt Disney Company, which gained 4.30 points or 3.98% to close at 112.43. Salesforce.com Inc rose 6.37 points or 3.50% to close at 188.61. Goldman Sachs Group Inc rose 11.29 points or 3.35% to close at 347.91. The losers were Merck & Company Inc, which shed 0.33 points (0.37%) to end the session at 89.19. UnitedHealth Group Incorporated was down 0.46 points (0.09%) to close at 537.72, while Walmart Inc was up 0.27 points (0.21%) to close at 129. fourteen. Among the gainers among the components of the S&P 500 in today''s trading were Norwegian Cruise Line Holdings Ltd, which rose 11.82% to 13.53, Royal Caribbean Cruises Ltd, which gained 9.74% to close at 41. 67, as well as shares of Carnival Corporation, which rose 9.19% to end the session at 10.34. The biggest losers were CME Group Inc, which shed 2.24% to close at 198.40.

Shares of micro-cap clinical-stage biotech Infinity Pharmaceuticals (INFI) jumped 24.3% to $0.92 in Wednesday mid-day trading, after it announced data from a two-year analysis of an…

During the last session, Infinity Pharmaceuticals Inc. (NASDAQ:INFI)’s traded shares were 0.76 million, with the beta value of the company hitting 2.07. At the end of the trading day, the stock’s price was $1.20, reflecting an intraday gain of 5.26% or $0.06. The 52-week high for the INFI share is $3.89, that puts it down … How Infinity Pharmaceuticals Inc. (NASDAQ: INFI) Could Be A Loss Maker Since It Is Down -46.67% YTD? Read More »

Shares of biotechnology company Infinity Pharmaceuticals <> soar as much as 28% a day after reporting better-than-expected FY revenue, helped by higher royalties.Company posts…

Infinity Pharmaceuticals press release (INFI): FY GAAP EPS of -$0.53 in-line.Revenue of $1.86M (+8.8% Y/Y) beats by $0.16M.Total cash, cash equivalents and available-for-sale…

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) (“Infinity” or the “Company”), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced its full year 2021 financial results and provided corporate highlights. “Based on the strength and breadth of eganelisib’s activity across mTNBC and mUC as well as ovarian cancer, SCCHN, and melanoma, we raised $92 million in early